Home » Stocks » BeyondSpring

BeyondSpring, Inc. (BYSI)

Stock Price: $14.77 USD -0.04 (-0.27%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 444.70M
Revenue (ttm) n/a
Net Income (ttm) -38.09M
Shares Out 27.89M
EPS (ttm) -1.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $14.77
Previous Close $14.81
Change ($) -0.04
Change (%) -0.27%
Day's Open 14.98
Day's Range 14.60 - 15.14
Day's Volume 72,648
52-Week Range 9.38 - 23.41

More Stats

Market Cap 444.70M
Enterprise Value 412.68M
Earnings Date (est) Aug 24, 2020
Ex-Dividend Date n/a
Shares Outstanding 27.89M
Float 13.86M
EPS (basic) -1.55
EPS (diluted) -1.82
FCF / Share -1.95
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 559,664
Short Ratio 10.74
Short % of Float 3.50%
Beta 1.16
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 25.46
Revenue n/a
Operating Income -40.31M
Net Income -38.09M
Free Cash Flow -48.17M
Net Cash 32.03M
Net Cash / Share 1.06
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -148.04%
ROE -10,243.33%
ROIC 701.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$42.50*
(187.75% upside)
Low
39.0
Current: 14.77
High
46.0
Target: 42.50
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014
Revenue------
Operating Income-40.31-57.23-97.06-12.37-7.50-2.11
Net Income-38.09-54.87-91.76-12.01-7.97-3.01
Shares Outstanding24.6522.6720.8716.0915.1713.91
Earnings Per Share-1.55-2.42-4.40-0.75-0.53-0.22
Operating Cash Flow-48.16-39.96-28.80-13.70-6.57-1.15
Capital Expenditures--0.21-0.08-0.06-0.04-
Free Cash Flow-48.17-40.16-28.87-13.76-6.61-1.15
Cash & Equivalents35.933.8930.5611.6910.820.00
Total Debt3.91-----
Net Cash / Debt32.033.8930.5611.6910.820.00
Assets44.567.0632.8314.9110.97-
Liabilities13.4216.454.792.611.31-
Book Value30.28-7.7727.0812.158.95-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name BeyondSpring, Inc.
Country United States
Employees 61
CEO Lan Huang

Stock Information

Ticker Symbol BYSI
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: BYSI
IPO Date March 9, 2017

Description

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin that is in late stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) for the prevention of high and intermediate risk chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a programmed cell death protein 1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody to treat small cell lung cancer; and death protein 1 or programmed death-ligand 1, an antibodies and radiation or chemotherapy for the treatment of multiple cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform using ubiquitin mediated protein degradation pathway. BeyondSpring Inc. has collaboration agreements with the Fred Hutchinson Cancer Research Center and the University of Washington. The company was founded in 2010 and is headquartered in New York, New York.